CA-125 and Ceruloplasmin Levels in Ovarian Cancer Patients

Year 2015, Volume: 40 Issue: 3, 510 - 516, 30.09.2015

Mangala Hegde Yousef Chianeh Jeevan Shetty Donald J Fernandes Pragna Rao

https://doi.org/10.17826/cutf.04830

Abstract

Purpose: The initial stage of proliferation of epithelial ovarian carcinoma (EOCa) is usually asymptomatic. Due to the lack of sensitive and reliable markers in majority of patients the disease is widespread at the time of diagnosis. The reliable serum biomarkers currently accepted is CA125 but there is limitation in case of sensitivity of CA125 as it is detectable only in 50% of patients in stage I and 80% of patients with advanced stage. We have investigated a correlation between serum CA125 and ceruloplasmin (as a marker of angiogenesis) in ovarian cancer in pre-treatment and post-treatment patients, compared with controls and found to be a significant marker for diagnosis. Material and Methods: A study was done in age group between 18-45 years diagnosed with ovarian cancer. (cases: n=50, controls: n=50). Cancer was diagnosed based on biopsy and histopathological examination. Serum Ceruloplasmin and CA 125 were estimated in pre-treatment and post-treatment patients and statistically significant decrease of these biomarkers observed in post treatment when compared with pre treatment patients. Result: We found that serum CA 125 to ceruloplasmin ratio was moderately increased in pre-treatment ovarian cancer patient. The serum ceruloplasmin (p<0.0001) level was significantly increased in ovarian cancer patients as compared to controls. Conclusion: Serum ceruloplasmin as well CA-125 level decline after treatment, and have been associated with efficacy and safety of novel therapeutic strategy to improve diagnosis and treatment for cancer

Keywords

Epithelial ovarian carcinoma (EOCa), Ceruloplasmin, Carbohydrate antigen 125 (CA-125)

Over Kanserli Hastalarda CA-125 ve Seruloplazmin Düzeyleri

Abstract

Amaç: Epitelial ovarian karsinomunda proliferasyonunun başlangıç aşaması genellikle asemptomatiktir. Hastaların büyük kısmında hassas ve güvenilir belirteçlerin eksikliği nedeni ile hastalık teşhis aşamasında artık yayılmış bulunmaktadır. Güvenilir olarak kabul edilen serum belirteci CA-125’tir ancak evre I hastalarının sadece %50’sinde ve ilerlemiş evre hastaların %80’ninde saptanabilmesinden dolayı, CA-125’in hassasiyeti konusunda bir sınırlama mevcuttur. Bu çalışmada, tedavi öncesi ve tedavi sonrası over kanserli hastalarda CA-125 ve seruloplazmin’in (anjiyogenez belirteci) serum seviyeleri arasındaki korelason araştırılmış, kontroller ile karşılaştırılmış ve teşhis için anlamlı bir belirteç olduğu bulunmuştur. Materyal ve Metod: Çalışma 18-45 yaş arası over kanseri teşhisi alan hastalar ile yapılmıştır (vaka n=50, kontrol n=50). Kanser teşhisi, biyopsi ve histopatolojik değerlendirme sonucu konulmuştur. Tedavi öncesi ve tedavi sonrası serum seruloplazmin ve CA-125 seviyeleri değerlendirilmiş ve tedavi öncesi ile karşılaştırıldığında, bu belirteçlerin tedavi sonrası hastalarda anlamlı derecede düştüğü gözlenmiştir. Sonuç: Serum CA-125 seruloplazmin oranı tedavi öncesi over kanserli hastalarda kısmen artmıştır. Serum seruloplazmin seviyesi (p<0.0001) kontrollerle karşılaştırıldığında over kanserli hastalarda anlamlı olarak yüksek bulunmştur. Tartışma: Seruloplazmin ve CA-125’in serumdaki seviyeleri tedaviden sonra azalmaktadır, buna bağlı olarak kanser tanı ve tedavisinde yeni tedavi stratejilerinin geliştirilmesinde güvenli ve etkili olabileceği düşünülmektedir.

Keywords

Epitelial Over Karsinom, Seruloplasmin, Karbohidrat antijen 125 (CA-125)

References

• Ginath S, Menczer J, Fintsi Y, Ben-Shem E, Glezerman M, Avinoach I. Tissue and serum CA125 expression in endometrial cancer. Int J Gynecol Cancer. 2002;12:372-5.
• A Jemal, R Siegel, J Xu, E Ward. Cancer statistics, CA: A Cancer Journal for Clinicians. 2010;60:277– 300.
• U Menon, IJ Jacobs. Recent developments in ovarian cancer screening. Current Opinion in Obstetrics and Gynecology. 2000;12:39–42.
• S. A. Cannistra. Cancer of the ovary. New England Journal of Medicine. 2004;351:2519–65.
• Nossov V, Amneus M, Su F, Lang J, Janco J. MT Reddy, ST Farias-Eisner R. the early detection of ovarian cancer: from proteomics. Can we really do better than serum CA- 125? Gynecology. 2008;199:215–23. of Obstetrics and
• LS Cohen, PF Escobar, C Scharm, B Glimco, DA Fishman. ultrasound improves the diagnostic accuracy for ovarian cancer prediction. Gynecologic Oncology. 2001;82:40–8.
• Bast Jr, R. C., Klug, T. L., John, E. S., Jenison, E., Niloff, J. M., Lazarus, H.,Knapp, R. C.. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med. 1983;309:883-7.
• BAST RC. Reactivity of a monoclonal antibody with human 1981;681:1331-7. J Clin Invest.
• Jacobs I, Bast RC Jr. CA125 tumour-associated antigen: A review of the literature. Hum Reprod. 1989;4:1-12.
• van Haaften‐Day, Carolien, Y U Shen, Fengji Xu, Yinhua Yu, Andrew Berchuck, Laura J. Havrilesky, HWA de Bruijn, Ate GJ van der Zee, Robert C. Bast, Neville F. Hacker. OVX1, CA 125 and M-CSF as tumor markers for surface epithelial-stromal tumors of the ovary: A critical appraisal. Cancer. 2001;92:2837- 44.
• Skates SJ, Jacobs IJ, MacDonald N, Menon U, Rosenthal AN. Estimated duration of pre-clinical ovarian cancer from longitudinal CA125 levels. Proc Am Assoc Cancer Res. 1999;43.
• Bast Jr RC, FP Siegal, C Runowicz, TL Klug, VR Zurawski Jr, D Schonholz, CJ Cohen, RC Knapp. Elevation of serum CA 125 prior to diagnosis of an epithelial ovarian 1985;22:115-20. Gynecol Oncol.
• Jacobs IJ, Skates S, Davies AP, Woolas RP, Jeyerajah A, Weidemann P. Karen Sibley, David H Oram. Risk of diagnosis of ovarian cancer after raised serum CA 125 concentration: A prospective cohort study. Br Med J. 1996;313:1355-8.
• Luza SC, Speisky HC. Liver copper storage and transport during development: implications for cytotoxicity. Am. J. Clin. Nutr. 1996;63:812-20.
• Cappelli-Bigazzi M, G Ambrosio, G Musci, C Battaglia, di Patti MC Bonaccorsi, P Golino, M Ragni, M Chiariello, L Calabrese.. Ceruloplasmin impairs endothelium-dependent relaxation of rabbit aorta. Am. J. Physiol 1997;273:H2843-H2849.
• Cappelli-Bigazzi M., Battaglia C., Pannain S., Chiariello M., Ambrosio G. Role of oxidative metabolism on endothelium-dependent vascular relaxation of isolated vessels. J. Mol. Cell. Cardiol. 1997;29:871-9.
• Bianchini A, Musci G, Calabrese L. Inhibition of endothelial nitric-oxide synthase by ceruloplasmin.J. Biol. Chem. 1999;274:20265-270.
• Patel B N, Dunn R J, Jeong S Y, Zhu Q, Julien J P, David S. Ceruloplasmin regulates iron levels in the CNS and prevents free radical injury. J. Neurosci. 2002;22:6578-86.
• Kondi-Pafiti A, Smyrniotis Papayanopoulou A, Englezou M, Deligeorgi H. Immunohistochemical lactoferrin and secretory component expression in neoplastic diseases.Acta Oncol. 2000;39:753-6. Frangou M, of
• ceruloplasmin, and thyroid gland
• Cox C, Teknos T N, Barrios M, Brewer G J, Dick R D, Merajver S D. The role of copper suppression as an antiangiogenic strategy in head and neck squamous 2001;111:696-701. Laryngoscope.
• Khandhadiya P K, Yousef Rezaei Chianeh, R Pragna. "Role of serum copper and ceruloplasmin level in patients with dysfunctional uterine bleeding." Int J Reprod Contracept Obstet Gynecol. 2014;3:333- 4.
• Chianeh Yousef Rezaei, Pragna Rao. Molecular and hormonal regulation of angiogenesis in proliferative endometrium. Int J Res Med Sci. 2014;2:1-9.
• Zhang Zhen, Robert C Bast, Yinhua Yu, Jinong Li, Lori J Sokoll, Alex J Rai, Jason M Rosenzweig, et al. Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer research. 2004;64 :5882-90.
• Nayak BS, Bhat VR, Upadhya D, Udupa SL. Copper and ceruloplasmin status in serum of prostate and colon 2003;47:108–10. Physiol Pharmacol.
• Steward AM, Niren D. Carcinoembryonic antigen in breast cancer patients. Cancer. 1974;33:1246–7.
• Concanon JP, Dawbow MH. Prognostic value of preoperative carcinoma. Cancer. 1978;142:1477–9.
• Lightman A, Brandes JM, Binur N, Drugan A, Zinder O. Use of the serum copper/zinc ratio in the differential diagnosis of ovarian malignancy. Clin Chem. 1986;32:1788–92.